Mucous In Heterogeneous And Progressive Early Cystic Fibrosis Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$347,948.00
Summary
Cystic fibrosis (CF) is the most common genetically acquired, life-shortening chronic illness affecting young Australians today. Individuals with CF have a reduced ability to clear mucous from the airways resulting in respiratory infections and inflammation. This project will quantify the biochemical and biophysical properties of mucous in young children with CF to generate novel insights into the pathogenesis of early disease, biomarkers of disease progression and therapeutic targets.
Biomarkers To Define The Treatment End-point For Pulmonary Exacerbations In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,031,371.00
Summary
Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis. A number of potential methods have emerged in recent years. We will investigate how these tests track an acute episode of lung disease and determine whether, following a typical course of treatment, there is evidence of residual damage that contributes to overall progression of lung disease.
The Role Of Tissue Hypoxia In The Evolution Of Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$509,391.00
Summary
We will determine how low oxygen levels in the kidney lead to kidney disease. We can now measure the levels of oxygen in kidney tissue in rats 24 hours a day, 7 days a week, in a completely non-invasive way. We will study two common kinds of kidney disease. One, acute kidney injury, can result from administration of contrast agents used in x-ray diagnostic procedures. The other, chronic kidney disease, is common in patients with diabetes or high blood pressure.